M. Dudley

Immunology · 2002–2015

A researcher in the Science corpus: 21 papers; trusts 5 researchers and is trusted by 12 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 153 citations into it; #487 of 2,160 by trust here, #139 by citations
• Oncology — 142 citations into it; #150 of 1,698 by trust here, #50 by citations
• Molecular Biology — 43 citations into it
• Genetics — 37 citations into it; #1,981 of 6,854 by trust here, #323 by citations

Whom M. Dudley trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Wunderlich
2. S. Rosenberg
3. Jie Yang
4. P. Matzinger
5. L. Gattinoni
6. D. Porter
7. Joseph C. Sun
8. L. Guidotti
9. N. Restifo
10. R. Morgan

Who trusts M. Dudley overall

1. S. Rosenberg
2. L. Gattinoni
3. N. Restifo
4. Jie Yang
5. W. Zou
6. P. Robbins
7. T. Gajewski
8. L. Zitvogel
9. Jennifer N. Brudno
10. R. Morgan

Papers from M. Dudley's perspective

Ordered by how strongly the researchers M. Dudley trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
3. Adoptive cell transfer: a clinical path to effective cancer immunotherapy (Nature Reviews. Cancer)
4. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
5. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (Journal of immunotherapy)
6. Final version of 2009 AJCC melanoma staging and classification. (Journal of Clinical Oncology)
7. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma (New England Journal of Medicine)
8. Adoptive immunotherapy for cancer: building on success (Nature reviews. Immunology)
9. Cancer immunotherapy: moving beyond current vaccines (Nature Medicine)
10. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (Science Translational Medicine)

Their papers

• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) — 1,605 citations
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (2010) — 1,314 citations
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. (2015) — 1,473 citations
• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. (2014) — 994 citations
• A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014) — 728 citations
• Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer (2014) — 1,637 citations
• Adoptive immunotherapy for cancer: harnessing the T cell response (2012) — 1,673 citations
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. (2012) — 1,404 citations
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy (2011) — 1,972 citations
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. (2011) — 813 citations
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. (2010) — 2,497 citations
• Adoptive Cell Therapy for the Treatment of Patients with Metastatic Melanoma (2009) — 626 citations
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. (2009) — 1,438 citations
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. (2009) — 1,711 citations
• Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008) — 1,698 citations
• Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens (2008) — 1,357 citations
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006) — 2,728 citations
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. (2005) — 1,709 citations
• Adoptive-cell-transfer therapy for the treatment of patients with cancer (2003) — 686 citations
• Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients (2003) — 702 citations